Print | Share | Contact Us | Search:


NPS Pharmaceuticals to Report First Quarter 2012 Financial Results


BEDMINSTER, N.J., Apr 27, 2012 (BUSINESS WIRE) --NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its first quarter 2012 financial results on Thursday, May 3, 2012 at approximately 4:30 p.m. ET. The press release will be followed by a conference call and webcast at 5:00 p.m. ET.

To participate in the conference call, dial (866) 788-0546 and use passcode 96110515. International callers may dial (857) 350-1684, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors' calendar of events page on the NPS website, http://www.npsp.com.

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 40466462 until midnight ET, May 17, 2012. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex(R) (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natpara(TM) (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Janssen Pharmaceuticals, Inc.

SOURCE: NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335




[Current Releases]
 
Stay informed


To stay apprised of NPS Pharmaceuticals press releases, financial reports and SEC filings as they are posted, sign up for Financial Alerts or SEC Alerts via email notification.

 


  Board of Directors
  Contact Us